UFP Technologies (UFPT) To Report Earnings Tomorrow: Here Is What To Expect

Medical products company UFP Technologies (NASDAQ:UFPT) will be announcing earnings results this Monday after market close. Here’s what to look for.

UFP Technologies beat analysts’ revenue expectations by 5.9% last quarter, reporting revenues of $148.1 million, up 41.1% year on year. It was an incredible quarter for the company, with a solid beat of analysts’ EPS estimates.

Is UFP Technologies a buy or sell going into earnings? Read our full analysis here, it’s free.

This quarter, analysts are expecting UFP Technologies’s revenue to grow 37.6% year on year to $151.6 million, improving from the 10.1% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $2.25 per share.

The majority of analysts covering the company have reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. UFP Technologies has only missed Wall Street’s revenue estimates once over the last two years, exceeding top-line expectations by 4.7% on average.

Looking at UFP Technologies’s peers in the drug development inputs & services segment, some have already reported their Q2 results, giving us a hint as to what we can expect. West Pharmaceutical Services delivered year-on-year revenue growth of 9.2%, beating analysts’ expectations by 5.6%, and Medpace reported revenues up 14.2%, topping estimates by 11.3%. West Pharmaceutical Services traded up 15.9% following the results while Medpace was also up 54.6%.

Read our full analysis of West Pharmaceutical Services’s results here and Medpace’s results here.

Debates around the economy’s health and the impact of potential tariffs and corporate tax cuts have caused much uncertainty in 2025. While some of the drug development inputs & services stocks have shown solid performance in this choppy environment, the group has generally underperformed, with share prices down 4.3% on average over the last month. UFP Technologies is down 6% during the same time and is heading into earnings with an average analyst price target of $311 (compared to the current share price of $226.56).

Unless you’ve been living under a rock, it should be obvious by now that generative AI is going to have a huge impact on how large corporations do business. While Nvidia and AMD are trading close to all-time highs, we prefer a lesser-known (but still profitable) semiconductor stock benefiting from the rise of AI. Click here to access our free report on our favorite semiconductor growth story.

StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.